Procept Cut Its 2026 Procedure View, but the Real Bet Is Q4 Profitability

The procedure cut matters more than the unchanged revenue target

The first read on PROCEPT's update is likely to be mechanical: investors see full-year revenue guidance of $390 million-$410 million hold and assume the story is intact. The more important signal, though, is the lower procedure outlook to 54,000-56,000 U.S. procedures. Revenue can hold up for a while through pricing and mix; procedure volume is the cleaner read on underlying demand.

PROCEPT did keep its revenue target after posting Q2 revenue of $94.5 million and completing more than 13,100 U.S. procedures in the quarter, up approximately 21%. But management said the shortfall was concentrated in legacy AquaBeam accounts, while HYDROS accounts continued to show stronger utilization. That makes this less about a broad growth crack and more about a transitional mix issue.

Why Q4 2026 adjusted EBITDA is the real checkpoint

If HYDROS-driven replacements keep lifting utilization, PROCEPT can preserve its revenue path even with fewer legacy-style procedures. But that only works if the higher-utilizing HYDROS mix is strong enough to offset softer output from older AquaBeam sites. If it is not, the unchanged revenue target starts to look more like support from pricing and mix than from durable demand.

That is why the market's focus should shift to profitability. Management still expects positive adjusted EBITDA in Q4 2026, so the next few quarters should show whether the mix story is turning into real operating leverage.

Investor Day still gives bulls a near-term roadmap

The bull case is not baseless. Investor Day laid out 2026 revenue growth of 27%–33% and 65% gross margin in 2026, improving to 68%–70% in 2027, along with positive adjusted EBITDA in Q4 2026 and a 2027 adjusted EBITDA gain of $25–30 million. That is specific enough to be a real operating test, not just a long-term narrative.

HYDROS adoption is the mechanism, but launch execution is the constraint

The key is not just placing more systems. It is placing the right systems and moving them into cases quickly after installation. PROCEPT sold 49 U.S. Hydros systems in Q1 and placed 65 HYDROS systems in the quarter, while management said procedures per HYDROS account were significantly higher than in legacy AquaBeam systems. If that pattern broadens, gross margin can hold and the fixed-cost base can support more profitable activity.

PROCEPT has also said the launch team now supports about 40% of new placements to improve time to first procedure and early utilization. That matters because robot adoption often breaks at the margin, where scheduling friction or slow early case flow can delay the whole loop.

The bear case is still simple: spending is up while the business remains unprofitable

Bears have a straightforward argument: higher spending has not yet produced profits. Full-year operating expenses now look like $355 million-$360 million, up because of higher spending on commercial initiatives, platform innovation, and clinical trials, and Q2 net loss widened to $26.9 million from $19.6 million a year earlier.

The rebuttal is timing. Gross margin was 66% in Q2, above the 65% reported a year earlier, even with heavier investment. If HYDROS mix keeps improving productivity, those expenses may look less like a permanent drag and more like the cost of reaching inflection.

What has to happen for the story to stay intact

The near-term breakpoint is still positive adjusted EBITDA in Q4 2026. Bulls still have a credible reason to believe that can happen: management continues to point to a large, underpenetrated opportunity in BPH and a proven user base with more than 125,000 patients treated to date. If that installed base and guideline support are translating into durable adoption, the current squeeze should look less like a ceiling and more like a costly ramp.

Bears, though, have a fair reaction to the procedure cut: the 2026 U.S. procedure outlook was lowered. That suggests adoption has been less smooth than the robotics narrative implies. The debate now is whether the remaining opportunity is converting into cases fast enough to support the profitability path.

The next two quarters need company-wide proof, not just isolated wins

A few high-utilization HYDROS accounts are not enough. The company needs to show that new placements and upgrades are broadening the advantage over legacy AquaBeam sites. Management has already said HYDROS accounts continue to perform well versus legacy AquaBeam, so the next reports must show that advantage moving from site-level anecdotes to consolidated economics.

Watchpoints

• Consolidated utilization: HYDROS outperformance has to matter at the company level, not just in isolated accounts.
• Expense discipline versus growth investment: spending can still rise, but margins need to keep improving.
• Handpiece conversion: lower handpiece uptake would weaken the argument that case flow is normalizing.
• WATER IV timing: enrollment is complete and results are a spring 2027 event, so they can extend the story later but will not rescue a missed near-term breakpoint.

What would invalidate the bullish setup

The bear case gets stronger if HYDROS outperformance stays too narrow to move consolidated results. If legacy AquaBeam weakness persists and the company cannot convert that advantage into broader case growth, the market will stop seeing operating leverage and start seeing guidance supported mainly by mix. In that scenario, Q4 2026 adjusted EBITDA breakeven becomes much harder to defend.